Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Why Has Mortality Related to Pancreatectomy Declined?

August 1, 2006
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 8
Volume 15
Issue 8

Nationally, the rate of in-hospital mortality associated with pancreatectomy for pancreatic cancer and other neoplasms has decreased in recent years

SAN FRANCISCO—Nationally, the rate of in-hospital mortality associated with pancreatectomy for pancreatic cancer and other neoplasms has decreased in recent years, researchers reported at the 2006 Gastrointestinal Cancers Symposium (abstract 94). Although a greater proportion of these procedures are now being done in higher-volume hospitals, this shift only partly explains the drop in mortality. Investigators at the University of Massachusetts Medical Center led by James T. McPhee, MD, used a nationally representative sample—the National Inpatient Sample—to study trends in outcomes of pancreatectomy for neoplasms between 1998 and 2003.

The overall rate of in-hospital mortality for the entire 6-year period was 5.8%, Dr. McPhee said. When the data were stratified by year, the rate decreased significantly, from 7.7% in 1998 to 4.4% in 2003. A regression analysis further confirmed the drop in mortality, indicating that this outcome fell by 0.42% per year.

The investigators next stratified hospitals by volume, in a way that maintained equal numbers of patients in each group. By this process, low-volume hospitals were those performing fewer than four pancreatectomies for neoplasms each year; medium-volume ones, 4 to 13 per year; and high-volume ones, more than 13 per year. For the entire 6-year period, the in-hospital mortality rate was 9.6%, 5.5%, and 2.1% in low-, medium-, and high-volume hospitals, respectively. As found among hospitals overall, the rate fell within each group during the study period: from 14% to 8.3% in the low-volume facilities, from 4.3% to 3.5% in the medium-volume ones, and from 2.8% to 2.0% in the high-volume ones.

In a multivariate analysis including seven factors (age, sex, hospital surgical volume, hospital teaching status, year of resection, payer status, and comorbid conditions), compared with patients operated on in high-volume hospitals, those operated on in medium-volume ones had more than double the risk of death (odds ratio, 2.4) and those operated on in low-volume hospitals had more than quadruple the risk (odds ratio, 4.1).

"Interestingly, while in the univariate analysis, hospital teaching status was correlated with operative mortality, with urban teaching hospitals having superior outcomes, when adjusted for the other variables, specifically hospital surgical volume, hospital teaching status then became insignificant," Dr. McPhee noted.

Paradigm Shift?

The observed temporal pattern of in-hospital mortality could not be explained by disproportionate sampling of hospitals of various volumes over time or by differing patient case mixes at hospitals with differing volumes, according to Dr. McPhee. "This prompted us to ask this question: Could the decrease in mortality over time reflect a paradigm shift whereby a higher percentage of pancreatic resections are being performed at the higher-volume surgical centers?" he said.

Further analysis supported at least some role for this phenomenon: From 1998 to 2003, the proportion of all resections done annually in high-volume hospitals increased from 32% to 40%, and for medium- or high-volume hospitals, from 60% to 69%.

In a final analysis, Dr. McPhee and his team calculated the contribution of this shift to the observed reduction in in-hospital mortality over time. This analysis showed that the shift accounted for a 0.8% drop in mortality during the 6-year period—only a modest part of the 3.3% drop actually observed.

Articles in this issue

Younger Age at Brain Tumor Diagnosis Portends Poor Emotional Outcome
Higher Responses in Metastatic Colon Ca When Cetuximab Added to Chemo
Triple Targeted Therapy Is Tested in Pts With Solid Tumors
FDA Approves Three-Drug Combination Tablet for HIV-1
Side Effects Persist 16 Years After Prostate Ca Brachytherapy
No Significant QOL Differences for Raloxifene and Tamoxifen
Amrubicin Appears Promising in Small-Cell Lung Cancer
R-MP Active in Older Pts With Newly Diagnosed Myeloma
Sunitinib and Sorafenib Active in Phase II Advanced NSCLC Trials
Takeda Signs Agreement With Galaxy Biotech for HuL2G7
Experimental Regimens Fail to Boost Pancreatic Survival
Adding Bortezomib Ups Dual Transplant Results in Myeloma
Demand Spurs Efforts to Improve Recruitment, Retention
Why Has Mortality Related to Pancreatectomy Declined?
Phase III Trial Finds XP as Efficacious as EP as First-Line Therapy for Metastatic Breast Cancer
Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Related Content
Advertisement

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.

FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs

Tim Cortese
November 14th 2025
Article

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.


Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.


Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.

Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs

Roman Fabbricatore
November 3rd 2025
Article

Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.


A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.


SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC

SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC

Ariana Pelosci
October 28th 2025
Article

Results from the SHARON trial presented at ESMO 2025 showed a potential treatment option for patients with PDAC who have BRCA1/2 or PALB2 mutations.


The safety profile of telisotuzumab adizutecan was manageable in pancreatic ductal adenocarcinoma, consistent with its profile in other tumor types.

Temab-A Displays Early Efficacy in Locally Advanced/Metastatic PDAC

Roman Fabbricatore
October 20th 2025
Article

The safety profile of telisotuzumab adizutecan was manageable in pancreatic ductal adenocarcinoma, consistent with its profile in other tumor types.

Related Content
Advertisement

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.

FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs

Tim Cortese
November 14th 2025
Article

Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.


Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.


Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.

Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs

Roman Fabbricatore
November 3rd 2025
Article

Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.


A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.


SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC

SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC

Ariana Pelosci
October 28th 2025
Article

Results from the SHARON trial presented at ESMO 2025 showed a potential treatment option for patients with PDAC who have BRCA1/2 or PALB2 mutations.


The safety profile of telisotuzumab adizutecan was manageable in pancreatic ductal adenocarcinoma, consistent with its profile in other tumor types.

Temab-A Displays Early Efficacy in Locally Advanced/Metastatic PDAC

Roman Fabbricatore
October 20th 2025
Article

The safety profile of telisotuzumab adizutecan was manageable in pancreatic ductal adenocarcinoma, consistent with its profile in other tumor types.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.